Imatinib Reverses Doxorubicin Resistance by Affecting Activation of STAT3-Dependent NF-κB and HSP27/p38/AKT Pathways and by Inhibiting ABCB1

Jonathan T. Sims(University of Kentucky), Rina Plattner(University of Kentucky)
PLoS ONE
January 31, 2013
Cited by 132


Related Papers